a designer of implantable lenses for the eye and delivery systems used to deliver lenses into the eye
Industry PharmaceuticalsOther
This is a Bullish indicator signaling STAA's price could rise from here. Traders may explore going long the stock or buying call options. A.I. dvisor identified 46 similar cases where STAA's MACD histogram became positive, and of them led to successful outcomes. Odds of Success:
STAA saw its Momentum Indicator move above the 0 level on September 03, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 102 similar instances where the indicator turned positive. In 78 of the 102 cases, the stock moved higher in the following days. The odds of a move higher are at 76%.
The Moving Average Convergence Divergence (MACD) for STAA just turned positive on September 02, 2026. Looking at past instances where STAA's MACD turned positive, the stock continued to rise in 35 of 46 cases over the following month. The odds of a continued upward trend are 76%.
Following a +6.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where STAA advanced for three days, in 192 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 48 cases where STAA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STAA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. STAA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.166) is normal, around the industry mean (4.967). P/E Ratio (288.312) is within average values for comparable stocks, (142.488). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.236). Dividend Yield (0.000) settles around the average of (0.015) among similar stocks. P/S Ratio (3.429) is also within normal values, averaging (74.760).
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STAA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.